Christopher Nathan Martin
CIK: 0002097992
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- Jul 27, 2026ACHV
ACHIEVE LIFE SCIENCES, INC.
Award(A)DirectRestricted Stock Unit (RSU)
16.7K shares- - Jul 27, 2026ACHV
ACHIEVE LIFE SCIENCES, INC.
Award(A)DirectStock Option (right to buy)
25K shares- - Jun 5, 2026EWTX
Edgewise Therapeutics, Inc.
Award(A)DirectStock Options (Right to buy)
16.4K shares- - Jun 2, 2026ORKA
Oruka Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
9.1K shares- - May 11, 2026ACHV
ACHIEVE LIFE SCIENCES, INC.
Award(A)DirectStock Option (right to buy)
47.3K shares- - Dec 11, 2025ORKA
Oruka Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
35K shares- - Nov 19, 2025EWTX
Edgewise Therapeutics, Inc.
Award(A)DirectStock Options (Right to buy)
45.2K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 27, 2026 |  ACHV ACHIEVE LIFE SCIENCES, INC. | Award(A) Restricted Stock Unit (RSU) | 16,700 | - | - | Direct |
| Jul 27, 2026 | ACHV ACHIEVE LIFE SCIENCES, INC. | Award(A) Stock Option (right to buy) | 25,000 | - | - | Direct |
| Jun 5, 2026 |  EWTX Edgewise Therapeutics, Inc. | Award(A) Stock Options (Right to buy) | 16,377 | - | - | Direct |
| Jun 2, 2026 |  ORKA Oruka Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 9,136 | - | - | Direct |
| May 11, 2026 | ACHV ACHIEVE LIFE SCIENCES, INC. | Award(A) Stock Option (right to buy) | 47,250 | - | - | Direct |
| Dec 11, 2025 | ORKA Oruka Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 35,000 | - | - | Direct |
| Nov 19, 2025 | EWTX Edgewise Therapeutics, Inc. | Award(A) Stock Options (Right to buy) | 45,150 | - | - | Direct |
1-7 of 7 transactions
About Martin Christopher Nathan
Martin Christopher Nathan (SEC CIK 0002097992) files insider reports with the SEC as Director of ACHIEVE LIFE SCIENCES, INC. (ACHV), Director of Edgewise Therapeutics, Inc. (EWTX) and Director of Oruka Therapeutics, Inc. (ORKA).
Signal8 holds 9 ownership filings by Martin Christopher Nathan (3 Form 3, 6 Form 4), filed between Nov 24, 2025 and Jul 29, 2026. Those filings report 7 transactions, from Nov 19, 2025 to Jul 27, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Martin Christopher Nathan's filings is in BOTHELL, WA.
Recent filings by Martin Christopher Nathan
- Jul 27, 2026: Grants or awards of ACHV derivative securities (2 lines, Form 4, code A).
- Jun 5, 2026: Grant or award of EWTX derivative securities (Form 4, code A).
- Jun 2, 2026: Grant or award of ORKA derivative securities (Form 4, code A).
- May 11, 2026: Grant or award of ACHV derivative securities (Form 4, code A).
- Dec 11, 2025: Grant or award of ORKA derivative securities (Form 4, code A).
Other insiders filing for ACHIEVE LIFE SCIENCES, INC. (ACHV)
- Halladay Benjamin, Chief Financial Officer
- Stewart Richard Alistair, Director
- Sellig Thomas, Director
- Royston Aaron, Director
- Waldman Reid Alexander, Director
- Farrow Jeffrey S, Director